{"id":2131,"date":"2017-08-11T01:27:14","date_gmt":"2017-08-10T23:27:14","guid":{"rendered":"https:\/\/www.aica3.org\/cms\/?p=2131"},"modified":"2017-08-11T01:34:07","modified_gmt":"2017-08-10T23:34:07","slug":"storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici","status":"publish","type":"post","link":"https:\/\/www.aica3.org\/cms\/en\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\/","title":{"rendered":"NATURAL HISTORY OF LGMD2A TO DELINEATE OUTCOME MEASURES IN CLINICAL TRIALS"},"content":{"rendered":"<p style=\"text-align: justify;\"><strong>NATURAL HISTORY OF LGMD2A FOR DELINEATING OUTCOME MEASURES IN CLINICAL TRIALS<\/strong><\/p>\n<p style=\"text-align: justify;\">Isabelle Richard, Jean Yves Hogrel , Daniel Stockholm et al<br \/>\n Annals of Clinical and Translational Neurology<br \/>\n 2016; 3 (4): 248-265<\/p>\n<p style=\"text-align: justify;\" class=\"translation-block\"><strong>INTRODUCTION<br> <\/strong>Girdle muscular dystrophy type LGMD2A (LGMD2A, OMIM) is a slowly progressive myopathy caused by deficiency of calpain 3, a calcium-dependent protease of skeletal muscle.<\/p>\n<p style=\"text-align: justify;\" class=\"translation-block\"><strong>METHODS<br> <\/strong>We conducted an observational study of clinical manifestations and disease progression over 4 years in patients with genetically confirmed LGMD2A . A total of 85 patients, aged 14-65 years, were recruited from 3 centers located in metropolitan France, the Basque region and Reunion Island. They were followed up every 6 months for 2 years, and a subgroup was evaluated annually for another 2 years thereafter.<\/p>\n<p style=\"text-align: justify;\">Data collected from all patients included medical history, hematochemical parameters, muscle strength measurement by manual muscle testing (MMT) and quantitative muscle testing, motor functional assessments and cardiac and respiratory function. In a subgroup of patients, a Computed Tomography of the lower limbs was also performed.<\/p>\n<p style=\"text-align: justify;\" class=\"translation-block\"><strong> RESULTS<br> <\/strong>Our study confirms the cynical description of a slowly progressive muscle disorder with onset in the first or second decade of life with a certain degree of variability related to sex and mutation type. Null mutations cause a more severe phenotype while patients carrying compound heterozygotes are less severely affected<\/p>\n<p style=\"text-align: justify;\">Muscle weakness is symmetrical and prevalent in the axial muscles of the trunk and proximal lower limbs. A high correlation is evident between the level of muscle impairment tested by MMT and the loss of density on analysis by computed tomography.<\/p>\n<p style=\"text-align: justify;\" class=\"translation-block\"><strong>INTERPRETATION<br> <\/strong>All data produced will help determine endpoints for possible future studies.<\/p>\n<p>&nbsp;<\/p>\n<blockquote>\n<p><a href=\"https:\/\/www.aica3.org\/cms\/wp-content\/uploads\/2017\/08\/Richard2016.pdf\"><strong>&gt;&gt; FULL ENGLISH ARTICLE &lt;&lt;<\/strong><\/a><\/p>\n<\/blockquote>","protected":false},"excerpt":{"rendered":"<p>NATURAL HISTORY OF LGMD2A FOR DELINEATING OUTCOME MEASURES IN CLINICAL TRIALS Isabelle Richard, Jean Yves Hogrel , Daniel Stockholm et al Annals of Clinical and Translational Neurology 2016; 3 (4): 248-265 INTRODUZIONE La distrofia muscolare dei cingoli tipo LGMD2A (LGMD2A, OMIM) \u00e8 una miopatia lentamente progressiva causata dal deficit di calpaina 3, una proteasi calcio [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[34,33],"tags":[],"class_list":["post-2131","post","type-post","status-publish","format-standard","hentry","category-articoli-scientifici","category-ricerca-e-pubblicazioni"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>STORIA NATURALE DELLE LGMD2A PER DELINEARE LE MISURE DI RISULTAT NEI TRIAL CLINICI - AICa3 - ETS - Associazione Italiana Calpaina 3<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.aica3.org\/cms\/en\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"STORIA NATURALE DELLE LGMD2A PER DELINEARE LE MISURE DI RISULTAT NEI TRIAL CLINICI - AICa3 - ETS - Associazione Italiana Calpaina 3\" \/>\n<meta property=\"og:description\" content=\"NATURAL HISTORY OF LGMD2A FOR DELINEATING OUTCOME MEASURES IN CLINICAL TRIALS Isabelle Richard, Jean Yves Hogrel , Daniel Stockholm et al Annals of Clinical and Translational Neurology 2016; 3 (4): 248-265 INTRODUZIONE La distrofia muscolare dei cingoli tipo LGMD2A (LGMD2A, OMIM) \u00e8 una miopatia lentamente progressiva causata dal deficit di calpaina 3, una proteasi calcio [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.aica3.org\/cms\/en\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\/\" \/>\n<meta property=\"og:site_name\" content=\"AICa3 - ETS - Associazione Italiana Calpaina 3\" \/>\n<meta property=\"article:publisher\" content=\"http:\/\/www.facebook.com\/pages\/AICa3-Associazione-Italiana-Calpaina-3\/119599211561350\" \/>\n<meta property=\"article:published_time\" content=\"2017-08-10T23:27:14+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2017-08-10T23:34:07+00:00\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\\\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/#\\\/schema\\\/person\\\/8a5e19b3ab1d1aa2190043f3ddb89aa2\"},\"headline\":\"STORIA NATURALE DELLE LGMD2A PER DELINEARE LE MISURE DI RISULTAT NEI TRIAL CLINICI\",\"datePublished\":\"2017-08-10T23:27:14+00:00\",\"dateModified\":\"2017-08-10T23:34:07+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\\\/\"},\"wordCount\":308,\"articleSection\":[\"Articoli scientifici\",\"Ricerca e Pubblicazioni\"],\"inLanguage\":\"en-GB\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\\\/\",\"url\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\\\/\",\"name\":\"STORIA NATURALE DELLE LGMD2A PER DELINEARE LE MISURE DI RISULTAT NEI TRIAL CLINICI - AICa3 - ETS - Associazione Italiana Calpaina 3\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/#website\"},\"datePublished\":\"2017-08-10T23:27:14+00:00\",\"dateModified\":\"2017-08-10T23:34:07+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/#\\\/schema\\\/person\\\/8a5e19b3ab1d1aa2190043f3ddb89aa2\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.aica3.org\\\/cms\\\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"STORIA NATURALE DELLE LGMD2A PER DELINEARE LE MISURE DI RISULTAT NEI TRIAL CLINICI\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/#website\",\"url\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/\",\"name\":\"AICa3 - ETS - Associazione Italiana Calpaina 3\",\"description\":\"Sito ufficiale dell\u2019Associazione Italiana Calpaina 3 per la lotta alla Distrofia Muscolare dei cingoli da deficit di Calpaina 3.\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/#\\\/schema\\\/person\\\/8a5e19b3ab1d1aa2190043f3ddb89aa2\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-GB\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b904785971eb1f4a705b7613434a976e92728da57cacd525748a7d680e4cccc?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b904785971eb1f4a705b7613434a976e92728da57cacd525748a7d680e4cccc?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/4b904785971eb1f4a705b7613434a976e92728da57cacd525748a7d680e4cccc?s=96&d=mm&r=g\",\"caption\":\"admin\"},\"url\":\"https:\\\/\\\/www.aica3.org\\\/cms\\\/en\\\/author\\\/admin\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"STORIA NATURALE DELLE LGMD2A PER DELINEARE LE MISURE DI RISULTAT NEI TRIAL CLINICI - AICa3 - ETS - Associazione Italiana Calpaina 3","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.aica3.org\/cms\/en\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\/","og_locale":"en_GB","og_type":"article","og_title":"STORIA NATURALE DELLE LGMD2A PER DELINEARE LE MISURE DI RISULTAT NEI TRIAL CLINICI - AICa3 - ETS - Associazione Italiana Calpaina 3","og_description":"NATURAL HISTORY OF LGMD2A FOR DELINEATING OUTCOME MEASURES IN CLINICAL TRIALS Isabelle Richard, Jean Yves Hogrel , Daniel Stockholm et al Annals of Clinical and Translational Neurology 2016; 3 (4): 248-265 INTRODUZIONE La distrofia muscolare dei cingoli tipo LGMD2A (LGMD2A, OMIM) \u00e8 una miopatia lentamente progressiva causata dal deficit di calpaina 3, una proteasi calcio [&hellip;]","og_url":"https:\/\/www.aica3.org\/cms\/en\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\/","og_site_name":"AICa3 - ETS - Associazione Italiana Calpaina 3","article_publisher":"http:\/\/www.facebook.com\/pages\/AICa3-Associazione-Italiana-Calpaina-3\/119599211561350","article_published_time":"2017-08-10T23:27:14+00:00","article_modified_time":"2017-08-10T23:34:07+00:00","author":"admin","twitter_misc":{"Written by":"admin","Estimated reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.aica3.org\/cms\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\/#article","isPartOf":{"@id":"https:\/\/www.aica3.org\/cms\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\/"},"author":{"name":"admin","@id":"https:\/\/www.aica3.org\/cms\/#\/schema\/person\/8a5e19b3ab1d1aa2190043f3ddb89aa2"},"headline":"STORIA NATURALE DELLE LGMD2A PER DELINEARE LE MISURE DI RISULTAT NEI TRIAL CLINICI","datePublished":"2017-08-10T23:27:14+00:00","dateModified":"2017-08-10T23:34:07+00:00","mainEntityOfPage":{"@id":"https:\/\/www.aica3.org\/cms\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\/"},"wordCount":308,"articleSection":["Articoli scientifici","Ricerca e Pubblicazioni"],"inLanguage":"en-GB"},{"@type":"WebPage","@id":"https:\/\/www.aica3.org\/cms\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\/","url":"https:\/\/www.aica3.org\/cms\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\/","name":"STORIA NATURALE DELLE LGMD2A PER DELINEARE LE MISURE DI RISULTAT NEI TRIAL CLINICI - AICa3 - ETS - Associazione Italiana Calpaina 3","isPartOf":{"@id":"https:\/\/www.aica3.org\/cms\/#website"},"datePublished":"2017-08-10T23:27:14+00:00","dateModified":"2017-08-10T23:34:07+00:00","author":{"@id":"https:\/\/www.aica3.org\/cms\/#\/schema\/person\/8a5e19b3ab1d1aa2190043f3ddb89aa2"},"breadcrumb":{"@id":"https:\/\/www.aica3.org\/cms\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.aica3.org\/cms\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.aica3.org\/cms\/storia-naturale-delle-lgmd2a-per-delineare-le-misure-di-risultat-nei-trial-clinici\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.aica3.org\/cms\/"},{"@type":"ListItem","position":2,"name":"STORIA NATURALE DELLE LGMD2A PER DELINEARE LE MISURE DI RISULTAT NEI TRIAL CLINICI"}]},{"@type":"WebSite","@id":"https:\/\/www.aica3.org\/cms\/#website","url":"https:\/\/www.aica3.org\/cms\/","name":"AICa3 - ETS - Associazione Italiana Calpaina 3","description":"Sito ufficiale dell\u2019Associazione Italiana Calpaina 3 per la lotta alla Distrofia Muscolare dei cingoli da deficit di Calpaina 3.","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.aica3.org\/cms\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"},{"@type":"Person","@id":"https:\/\/www.aica3.org\/cms\/#\/schema\/person\/8a5e19b3ab1d1aa2190043f3ddb89aa2","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-GB","@id":"https:\/\/secure.gravatar.com\/avatar\/4b904785971eb1f4a705b7613434a976e92728da57cacd525748a7d680e4cccc?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/4b904785971eb1f4a705b7613434a976e92728da57cacd525748a7d680e4cccc?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/4b904785971eb1f4a705b7613434a976e92728da57cacd525748a7d680e4cccc?s=96&d=mm&r=g","caption":"admin"},"url":"https:\/\/www.aica3.org\/cms\/en\/author\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/www.aica3.org\/cms\/en\/wp-json\/wp\/v2\/posts\/2131","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.aica3.org\/cms\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.aica3.org\/cms\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.aica3.org\/cms\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/www.aica3.org\/cms\/en\/wp-json\/wp\/v2\/comments?post=2131"}],"version-history":[{"count":0,"href":"https:\/\/www.aica3.org\/cms\/en\/wp-json\/wp\/v2\/posts\/2131\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.aica3.org\/cms\/en\/wp-json\/wp\/v2\/media?parent=2131"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.aica3.org\/cms\/en\/wp-json\/wp\/v2\/categories?post=2131"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.aica3.org\/cms\/en\/wp-json\/wp\/v2\/tags?post=2131"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}